nach oben

Drugs

Erschienen in:

01.07.2014 | R&D Insight Report

Siltuximab: First Global Approval

verfasst von: Anthony Markham, Trina Patel

Erschienen in: Drugs | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

The anti-interleukin-6 (IL-6) chimeric monoclonal antibody siltuximab is the first drug to be approved for the treatment of multicentric Castleman’s disease (MCD) in the US and European union (EU), having gained approval under the FDA priority review program in the US and from an accelerated assessment and recommendation by the Committee for Medicinal Products for Human Use (CHMP) in the EU. Development of the drug is continuing in smoldering multiple myeloma. This article summarizes the milestones in the development of siltuximab leading to this first approval for MCD.

Van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8(7):486–98.PubMed

El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497–511.PubMedCentralPubMedCrossRef

Fajgenbaum D, van Rhee F, Nabel C. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014. doi:10.1182/blood-2013-12-545087.PubMed

Chugai Pharmaceutical. Chugai Pharmaceutical’s innovative Castleman’s disease drug ACTEMRA now available in Japan (media release), 14 June 2005. www.japancorp.net.

US Food and Drug Administration. FDA approves Sylvant for rare Castleman’s disease (media release), 23 April 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394522.htm.

Janssen Biotech. SYLVANT(Tm) (siltuximab) Receives FDA Approval to treat multicentric Castleman’s disease (MCD): first treatment approved for patients with rare blood disorder (media release), 23 April 2014. http://www.janssenbiotech.com.

US Food and Drug Administration. SYLVANT prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf. Accessed 15 May 2014.

European Commission. Community register of medicinal products for human use: SYLANT authorisation 2014. http://ec.europa.eu/health/documents/community-register/html/h928.htm. Accessed 10 Jun 2014.

Committee for Medicinal Products for Human Use (CHMP) EMA. Summary of opinion (initial authorisation) Sylvant Siltuximab. 2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/03/WC500163529.pdf.

10.

Guo Y, Nemeth J, O’Brien C, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010;16(23):5759–69.PubMedCrossRef

11.

Cavarretta IT, Neuwirt H, Zaki MH, et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol. 2008;617:547–55.PubMedCrossRef

12.

Hunsucker SA, Magarotto V, Kuhn DJ, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011;152(5):579–92.PubMedCentralPubMedCrossRef

13.

Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 2009;145(4):481–90.PubMedCentralPubMedCrossRef

14.

Karkera J, Steiner H, Li W, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011;71(13):1455–65.PubMedCrossRef

15.

van Zaanen HC, Koopmans RP, Aarden LA, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest. 1996;98(6):1441–8.PubMedCentralPubMedCrossRef

16.

Coward J, Kulbe H, Leader D, et al. Interleukin-6 as a therapeutic target in advanced ovarian cancer [abstract no. 5331]. In: 101st Annual Meeting of the American Association for Cancer Research; 17-21 Apr 2010; Washington, DC.

17.

Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653–65.PubMedCentralPubMed

18.

Puchalski T, Prabhakar U, Jiao Q, et al. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010;16(5):1652–61.PubMedCrossRef

19.

Xie L, Li LY, Kurzrock R, et al. Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody, siltuximab (CNTO 328), in patients with B-cell non-Hodgkin’s lymphoma, multiple myeloma, or Castleman’s disease. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).

20.

Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19(13):3659–70.PubMedCrossRef

21.

Angevin E, Elez E, Cohen SJ, et al. Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors [abstract no. 2583]. J Clin Oncol Conf. 2012;30(15 suppl).

22.

Wong RS, Casper C, Munshi N, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).

23.

Van Rhee F, Casper C, Voorhees PM, et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).

24.

Kirk M, Kurzrock R, Van Rhee F, et al. Siltuximab reverses muscle wasting in patients with multicentric Castleman’s disease. In: Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21).

25.

San Miguel J, Blade J, Shpilberg O, et al. Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma. Blood. 2014. doi:10.1182/blood-2013-12-546374.

26.

Orlowski RZ, Gercheva L, Williams C, et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/ refractory multiple myeloma [abstract no. 8018]. J Clin Oncol 2012;30(Suppl).

27.

Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161(3):357–66.PubMedCrossRef

Titel: Siltuximab: First Global Approval
verfasst von: Anthony Markham
Trina Patel
Publikationsdatum: 01.07.2014
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 10/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-014-0249-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Pazopanib: A Review of Its Use in the Management of Advanced Renal Cell Carcinoma

Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia

Vorapaxar: First Global Approval

Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?

Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs

Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and Therapy